See more : Sciuker Frames S.p.A. (SCK.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Centogene N.V. (CNTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Centogene N.V., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Endesa, S.A. (ELEZF) Income Statement Analysis – Financial Results
- Arrowroot Acquisition Corp. (AILEW) Income Statement Analysis – Financial Results
- Venus Acquisition Corporation (VENAR) Income Statement Analysis – Financial Results
- Southern Cross Gold Ltd (SXG.AX) Income Statement Analysis – Financial Results
- Global Blood Therapeutics, Inc. (GBT) Income Statement Analysis – Financial Results
Centogene N.V. (CNTG)
About Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.54M | 47.47M | 189.92M | 128.38M | 48.78M | 40.48M | 31.69M | 27.67M |
| Cost of Revenue | 35.93M | 27.71M | 161.77M | 86.38M | 26.01M | 19.94M | 14.94M | 12.86M |
| Gross Profit | 11.61M | 19.76M | 28.16M | 42.00M | 22.78M | 20.54M | 16.75M | 14.81M |
| Gross Profit Ratio | 24.42% | 41.63% | 14.83% | 32.72% | 46.69% | 50.74% | 52.86% | 53.54% |
| Research & Development | 10.17M | 17.49M | 19.30M | 14.94M | 9.59M | 6.30M | 6.40M | 5.89M |
| General & Administrative | 29.17M | 29.21M | 44.79M | 37.67M | 23.16M | 18.61M | 9.50M | 8.89M |
| Selling & Marketing | 12.56M | 9.92M | 9.86M | 7.58M | 9.25M | 7.47M | 5.90M | 5.36M |
| SG&A | 41.68M | 39.13M | 54.65M | 45.25M | 32.41M | 26.08M | 15.40M | 14.25M |
| Other Expenses | 1.91M | -340.00K | -970.00K | -2.22M | 109.00K | -2.14M | 0.00 | 290.51K |
| Operating Expenses | 49.93M | 56.28M | 72.98M | 57.96M | 42.11M | 30.25M | 21.28M | 19.21M |
| Cost & Expenses | 85.86M | 83.99M | 234.74M | 144.34M | 68.12M | 50.19M | 36.22M | 32.07M |
| Interest Income | 209.00K | 3.00K | 3.00K | 6.00K | 16.00K | 33.00K | 14.00K | 26.00K |
| Interest Expense | 8.20M | 3.57M | 851.00K | 1.04M | 2.03M | 1.08M | 1.02M | 829.00K |
| Depreciation & Amortization | 7.45M | 10.19M | 20.77M | 14.09M | 6.56M | 5.34M | 3.04M | 2.19M |
| EBITDA | -30.87M | -26.00M | -41.03M | -50.12M | -12.74M | -5.40M | -1.29M | -2.94M |
| EBITDA Ratio | -64.93% | -54.77% | -12.39% | -0.64% | -26.12% | -11.12% | -4.04% | -8.28% |
| Operating Income | -38.32M | -36.52M | -44.82M | -15.96M | -19.34M | -10.61M | -4.46M | -4.94M |
| Operating Income Ratio | -80.61% | -76.92% | -23.60% | -12.43% | -39.64% | -26.20% | -14.06% | -17.84% |
| Total Other Income/Expenses | 3.08M | -1.82M | -4.22M | 32.63M | -1.36M | -1.94M | -1.01M | -741.00K |
| Income Before Tax | -34.23M | -38.60M | -46.88M | -21.10M | -20.70M | -11.65M | -5.46M | -5.77M |
| Income Before Tax Ratio | -71.99% | -81.30% | -24.68% | -16.43% | -42.43% | -28.78% | -17.24% | -20.84% |
| Income Tax Expense | 281.12K | 107.00K | -24.00K | 281.00K | 158.00K | -310.00K | 14.00K | -408.00K |
| Net Income | -34.80M | -38.70M | -46.85M | -21.38M | -20.86M | -11.34M | -5.48M | -5.36M |
| Net Income Ratio | -73.21% | -81.53% | -24.67% | -16.65% | -42.75% | -28.01% | -17.28% | -19.37% |
| EPS | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| EPS Diluted | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| Weighted Avg Shares Out | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
| Weighted Avg Shares Out (Dil) | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript
Recap: Centogene Q3 Earnings
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
CENTOGENE Announces Nomination of Jonathan Sheldon to Supervisory Board
Fujirebio Europe and CENTOGENE Enter Partnership to Provide Rapid and High-Quality Preventive SARS-CoV-2 Antigen Testing
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Berlin Brandenburg Airport
Veracyte (NASDAQ:VCYT) versus Centogene (NASDAQ:CNTG) Financial Comparison
Source: https://incomestatements.info
Category: Stock Reports